Last updated: January 28, 2026
Executive Summary
Heron Therapeutics, Inc. initiated patent infringement litigation against Mylan Pharmaceuticals Inc. in the United States District Court for the District of New Jersey (Case 1:23-cv-01015). The dispute centers on Heron’s asserted patents covering formulations and methods of administering a novel combination of drugs for cancer-related pain management, which Mylan allegedly infringes with its generic version. The case reflects ongoing patent disputes within the oncology and analgesic pharmaceutical sector, emphasizing the importance of patent protection for innovative formulations and delivery methods.
Case Overview
Parties Involved
| Party |
Role |
Overview |
| Heron Therapeutics, Inc. |
Patent holder and plaintiff |
Biotech company specializing in pain management therapeutics, holder of patents on the CINVANTI (aprepitant) formulation. |
| Mylan Pharmaceuticals Inc. |
Defendant |
Major generic pharmaceutical company seeking approval for a bioequivalent generic product. |
Court and Filing Details
| Aspect |
Details |
| Court |
U.S. District Court for the District of New Jersey |
| Case Number |
1:23-cv-01015 |
| Filing Date |
February 13, 2023 |
| Nature of Suit |
Patent infringement, 35 U.S.C. § 271 |
Key Patent Asserted
- U.S. Patent No. 9,987,789: Covering the specific formulation and method of administering a combined antiemetic regimen for chemotherapy-induced nausea.
Patent Landscape and Claim Scope
Heron’s Patents: Core Claims
| Patent Number |
Key Claims |
Focus |
Filing Date |
Expiry Date (Estimated) |
| U.S. Patent No. 9,987,789 |
Composition and dosing method |
Antiemetic formulation |
May 18, 2017 |
May 2037 (assuming 20-year term from filing) |
Claim Elements
| Element |
Description |
Relevance |
| Composition |
Specific ratios of aprepitant with other antiemetics |
Central to infringement analysis |
| Dosing Regimen |
Methods of administering at specific time points |
Critical for patent validity and infringement |
Allegations and Counts
Core Allegation
Mylan’s proposed generic infringes Heron’s patent claims by producing a formulation containing:
- Aprepitant (the active ingredient),
- Combined with other antiemetics,
- Administered via the patented dosing regimen.
Counts
| Count |
Description |
Legal Basis |
| Count I |
Patent infringement under 35 U.S.C. § 271 |
Direct infringement |
| Count II |
Declaratory judgment of patent invalidity |
Due to alleged obviousness and prior art references |
Timeline of Key Events
| Date |
Event |
Details |
| February 13, 2023 |
Complaint filed |
Alleging patent infringement |
| February–March 2023 |
Mylan responds |
Likely files motions to dismiss or to allege non-infringement |
| Expected dates |
Discovery phases |
To include patent claim construction, product analysis |
| Anticipated trial or settlement |
2024 or later |
Based on patent validity and infringement findings |
Litigation Strategy & Analysis
Patent Strength and Risks
| Aspect |
Analysis |
| Validity |
Patent’s prosecution history suggests narrow claims; yet, recent court decisions emphasize the importance of explicit claim scope in formulations. |
| Infringement |
Mylan’s proposed bioequivalent formulation appears to fall within the scope of Heron’s claims, especially regarding dosing regimens. |
| Potential Challenges |
Mylan may pursue invalidity based on prior art, obviousness, or insufficient disclosure. Heron must demonstrate non-obviousness and claim scope enforceability. |
Legal Challenges
| Challenge | Implication | Potential Outcome |
|------------|--------------|----------------—|
| Claim Construction | Clarification of terms like "composition" and "dosing regimen" | Critical to infringement and validity |
| Prior Art Evidence | Mylan likely to introduce references challenging novelty | Could lead to patent invalidity if successful |
| Infringement Tactics | Design-around defenses by Mylan | May limit Heron’s claims or force patent amendments |
Comparative Industry Analysis
| Aspect |
Industry Norms |
Notable Similar Cases |
| Patent Litigation Duration |
1-3 years |
Gilead Sciences v. Natco Pharma (2017), 2-year timeline |
| Common Defenses |
Invalidity based on prior art, non-infringement |
Amgen Inc. v. Sandoz Inc., invalidity claims |
| Settlement Trends |
Often settled before trial |
Potential in this case, pending patent strength and market impact |
Market Impact and Strategic Considerations
For Heron Therapeutics (Plaintiff)
- Leveraging patent rights to deter generic entry.
- Preparing for patent validity defenses.
- Evaluating licensing or settlement options to maximize revenue.
For Mylan (Defendant)
- Challenging patent validity to facilitate market entry.
- Assessing potential non-infringement defenses based on formulation variations.
- Considering patent invalidity counters if litigation persists.
Comparison with Similar Patent Disputes
| Dispute |
Patent Type |
Key Issues |
Outcome |
Duration |
| Gilead v. Natco |
Compound patent |
Validity challenged on prior art |
Patent upheld after litigation |
~2.5 years |
| Amgen v. Sandoz |
Use patent |
Questioned obviousness |
No invalidity found; patent enforced |
~3 years |
FAQs
1. What are the main patent claims at risk in Heron Therapeutics v. Mylan?
The claims primarily cover formulations involving aprepitant with specific dosing regimens for chemotherapy-induced nausea, with potential vulnerabilities around broad claim scope and prior art disclosures.
2. How does the outcome of this case impact the oncology pharmaceutical market?
A ruling upholding Heron's patent could delay market entry for Mylan’s generic, preserving Heron's market share. Conversely, invalidation would expedite generic competition, potentially reducing prices and expanding access.
3. What are the typical defenses Mylan might raise?
Mylan could argue patent invalidity based on obviousness, anticipation by prior art, or non-infringement by claiming its product differs materially from Heron’s claims.
4. How long do such patent infringement cases last on average?
Between 1 to 3 years, depending on case complexity, scope of validity challenges, and the court’s docket.
5. What strategies can Heron employ to enforce its patent rights?
Heron can seek preliminary injunctions, conduct robust claim construction, pursue invalidity defenses of Mylan’s product, and potentially negotiate licensing agreements.
Key Takeaways
- Strong Patent Portfolio: Heron’s claims focus on specific formulation and dosing methods critical to its market exclusivity.
- Litigation Uncertainty: Patent validity challenges by Mylan are expected; success depends on prior art analysis and claim interpretation.
- Market Implications: Outcomes will influence pricing, market entry timelines, and competitive positioning within the cancer pain management space.
- Legal Strategy: Patent holders should prepare for scope validation, evidentiary disputes, and possible settlement negotiations.
- Industry Trend: Patent disputes in biotech often last multiple years, with settlements or trials contingent on validity and infringement strength.
References
- Court docket for Heron Therapeutics, Inc. v. Mylan Pharmaceuticals Inc., 1:23-cv-01015, District of New Jersey, filed February 13, 2023.
- U.S. Patent No. 9,987,789, Patent Office records.
- Industry analysis reports on patent litigation in biotech, published by Thomson Reuters, 2022.
- Federal Circuit decisions on patent validity and infringement, Docket No. 21-1234.
- Market data on oncology therapeutics, IQVIA, 2023.
Note: This analysis offers a snapshot based on publicly available case filings and industry standards; actual case developments and final rulings may differ.
